1. Home
  2. MLYS vs EVLV Comparison

MLYS vs EVLV Comparison

Compare MLYS & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$29.40

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Evolv Technologies Holdings Inc.

EVLV

Evolv Technologies Holdings Inc.

HOLD

Current Price

$4.98

Market Cap

994.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
EVLV
Founded
2019
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
994.7M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
EVLV
Price
$29.40
$4.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
$48.67
$9.13
AVG Volume (30 Days)
997.6K
1.8M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
41.18
EPS
N/A
N/A
Revenue
N/A
$145,905,000.00
Revenue This Year
N/A
$21.67
Revenue Next Year
N/A
$19.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.48
52 Week Low
$22.30
$4.61
52 Week High
$47.65
$8.81

Technical Indicators

Market Signals
Indicator
MLYS
EVLV
Relative Strength Index (RSI) 60.46 37.72
Support Level $25.34 $4.87
Resistance Level $31.26 $5.86
Average True Range (ATR) 1.40 0.17
MACD 0.49 -0.03
Stochastic Oscillator 65.06 15.30

Price Performance

Historical Comparison
MLYS
EVLV

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: